← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
CGTBiologicNovartis PharmaceuticalsPhase 2

cytogenetic analysis (cytogenetic analysis)

Chronic Myeloproliferative Disorders; Leukemia · Colorectal Cancer

#ColorectalCancer#CGT#Phase2#인기#세포유전치료+5
임상시험 54상태 ACTIVE
ADCBiologicQuantumLeap Healthcare Collabor…Phase 2

ABT-888 (ABT-888)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 74.1%임상시험 53상태 RECRUITING
AntibodyRocheVedotin on Brain Metastases…Phase 2

atezolizumab (Tecentriq, Atezolizumab - 28 Day Cycle)

Endometrial Cancer · Endometrial Cancer

#EndometrialCancer#Antibody#Phase2#인기#항체+5
효능 ORR 90%임상시험 53상태 RECRUITING
CGTBiologicKitevedotin plus bendamustine a…Approved

axicabtagene ciloleucel (Yescarta, axi-cel)

Large B-cell Lymphoma; Lymphoma, B-Cell · FRα

#FR#CGT#Approved#인기#세포유전치료+5
효능 ORR 92%임상시험 53상태 RECRUITING
AntibodyAstraZenecaPreclinical

Benralizumab (Benralizumab)

Asthma · Asthma

#Asthma#Antibody#Preclinical#인기#항체+4
임상시험 53상태 ACTIVE
CGTBiologicHebei Senlang Biotechnology Inc…Preclinical

CD19+CD22 CAR-T (CD19+CD22 CAR-T)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#인기#세포유전치료+5
임상시험 53상태 ACTIVE
CGTBiologicCRISPR Therapeutics AGPhase 2

CD19-directed CAR-T cells (CD19-directed CAR-T cells)

B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 25%임상시험 53상태 ACTIVE
CGTBiologicMatthew FrankPhase 1

CD22 CAR (CD22 CAR)

B-ALL; B-cell Non Hodgkin Lymphoma · CD22

#CD22#CGT#Phase1#인기#세포유전치료+5
임상시험 53상태 ACTIVE
CGTBiologicHebei Senlang Biotechnology Inc…Phase 1

CD22 CAR-T (CD22 CAR-T)

Childhood Acute Lymphoblastic Leukemia · CD22

#CD22#CGT#Phase1#인기#세포유전치료+5
임상시험 53상태 ACTIVE
ADCBiologicDaiichi Sankyoderuxtecan (T-DXd) in FISH-…Phase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, DS-8201a)

Colorectal Neoplasm · Malignant Neoplasm of Breast

#MalignantNeoplasmofBreast#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 74.1%임상시험 53상태 DISCONTINUED
CGTBiologicGlaxoSmithKlinePhase 2

Eltrombopag (Eltrombopag)

Immune Thrombocytopenic Purpura · Chronic Granulomatous Disease (CGD)

#ChronicGranulomatousDiseaseCGD#CGT#Phase2#인기#세포유전치료+5
효능 ORR 10%임상시험 53상태 ACTIVE
ADCBiologicJiangsu HengRui Medicine Co., L…Phase 2

Famitinib (Famitinib)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
임상시험 53상태 RECRUITING
ADCBiologicGilead Sciencesderuxtecan (OR 4Phase 3

Idelalisib (Idelalisib)

Chronic Lymphocytic Leukaemia · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 90.9%임상시험 53상태 DISCONTINUED
ADCBiologicAdenoid Cystic Carcinoma Resear…Phase 1

IMD (Implantable Microdevice, Implantable Microdevice (IMD))

Triple Negative Breast Cancer; Breast Cancer Stage II · Triple Negative Breast Cancer

#TripleNegativeBreastCancer#ADC#Phase1#인기#항체약물접합체+3
효능 ORR 0.1%임상시험 53상태 DISCONTINUED
AntibodyEli Lilly and CompanyApproved

Ixekizumab (Ixekizumab)

Psoriasis; Atopic Dermatitis · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Approved#인기#항체+5
임상시험 53상태 RECRUITING
ADCBiologicVadim S Koshkinvedotin (BT8009) and dual-A…Phase 1

N803 (Nogapendekin Alfa Inbakicept, Nogapendekin Alfa Inbakicept (N803))

Metastatic Urothelial Carcinoma; Urothelial Carcinoma · Metastatic Urothelial Carcinoma

#MetastaticUrothelialCarcinoma#ADC#Phase1#인기#항체약물접합체+5
효능 ORR 80%임상시험 53상태 DISCONTINUED
ADCBiologicCelgeneVedotinPhase 1

Romidepsin (Romidepsin)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · Cutaneous T-cell Lymphoma (CTCL)

#CutaneousT-cellLymphomaCTCL#ADC#Phase1#인기#항체약물접합체+5
효능 ORR 50%임상시험 53상태 ACTIVE
ADCBiologicKing Abdullah International Med…Vedotin Plus AVD versus ABV…Phase 2

ABVD (ABVD)

Classical Hodgkin Lymphoma; Hodgkin Lymphoma (Category) · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 96%임상시험 52상태 ACTIVE
ADCBiologicGSKinPhase 1

Belantamab (Belantamab)

Autoimmune Diseases · Autoimmune Diseases

#AutoimmuneDiseases#ADC#Phase1#인기#항체약물접합체+4
효능 ORR 40%임상시험 52상태 DISCONTINUED
AntibodyRochePreclinical

Bevacizumab + Erlotinib (Bevacizumab + Erlotinib)

Solid Tumor; Advanced Solid Tumor · Solid Tumor

#SolidTumor#Antibody#Preclinical#인기#항체+4
효능 ORR 72%임상시험 52상태 RECRUITING

21 / 209 페이지

← 이전다음 →